Chardan Capital Reduces Earnings Estimates for Metagenomi

Key Points

• Chardan Capital has lowered its FY2025 earnings estimate for Metagenomi to ($2.34) per share, down from a previous estimate of ($1.44), while maintaining a "Buy" rating with a target price of $11.00.
• Metagenomi's most recent earnings report showed a loss of ($0.54) EPS, which exceeded analysts' expectations of ($0.68), along with revenue of $8.51 million compared to a consensus estimate of $7.72 million.
• Several institutional investors have increased their stakes in Metagenomi, with Pura Vida Investments LLC increasing its position by 260.1% during the second quarter.

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Stock analysts at Chardan Capital reduced their FY2025 earnings estimates for Metagenomi in a research report issued on Monday, August 18th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per share of ($2.34) for the year, down from their previous forecast of ($1.44). Chardan Capital has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi's FY2026 earnings at ($1.20) EPS.

Several other equities analysts have also issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Metagenomi in a report on Tuesday. Wall Street Zen lowered shares of Metagenomi from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Finally, Wells Fargo & Company lowered their target price on shares of Metagenomi from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, August 14th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $10.00.

Metagenomi Stock Performance

MGX stock opened at $1.85 on Thursday. The firm has a 50 day moving average price of $1.91 and a 200-day moving average price of $1.84. Metagenomi has a 52-week low of $1.23 and a 52-week high of $4.92. The firm has a market capitalization of $69.43 million, a price-to-earnings ratio of -0.78 and a beta of -0.12.

Metagenomi (NASDAQ:MGX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.14. Metagenomi had a negative net margin of 257.99% and a negative return on equity of 37.84%. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $7.72 million.

Institutional Investors Weigh In On Metagenomi

Several institutional investors and hedge funds have recently made changes to their positions in the company. Pura Vida Investments LLC increased its position in shares of Metagenomi by 260.1% during the second quarter. Pura Vida Investments LLC now owns 952,134 shares of the company's stock valued at $1,409,000 after acquiring an additional 687,743 shares in the last quarter. Geode Capital Management LLC grew its position in Metagenomi by 73.8% in the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock worth $2,121,000 after purchasing an additional 249,390 shares during the period. Peapod Lane Capital LLC grew its position in Metagenomi by 44.2% in the 2nd quarter. Peapod Lane Capital LLC now owns 508,109 shares of the company's stock worth $752,000 after purchasing an additional 155,652 shares during the period. Norges Bank bought a new stake in Metagenomi in the 2nd quarter worth approximately $373,000. Finally, Northern Trust Corp grew its position in Metagenomi by 185.6% in the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company's stock worth $808,000 after purchasing an additional 145,536 shares during the period.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.